Tsai YA. Comment on "Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network" by Katherine Benandi et al. J Am Acad Dermatol 2025 Dec 11:S0190-9622(25)03365.
PMID: 41390130